MetaCap

Corcept Therapeutics (CORT) vs Rhythm Pharmaceuticals (RYTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rhythm Pharmaceuticals (RYTM) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 10.4% versus a loss of 17.7%. Over five years, RYTM leads with a +1116.0% price change compared with +196.0% for CORT. Rhythm Pharmaceuticals is the larger company by market cap ($7.79 billion vs $6.96 billion), about 1.1 times the size.

Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -103.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CORT-17.69%RYTM+10.44%
+66%+1%-64%
Nov 21, 20251 yearNov 20, 2026
CORT+178.18%RYTM+990.87%
+1077%+477%-123%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CORT versus RYTM key metrics
MetricCORTRYTM
Share price$63.62$112.36
Market cap$6.96B$7.79B
1-day change-2.09%-3.80%
YTD return+82.82%+4.97%
1-year return-17.69%+10.44%
5-year return+196.04%+1116.02%
P/E ratio (TTM)47.83—
Forward P/E12.77—
EPS (TTM)$1.33$-2.91
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$761.41M$189.76M
Revenue growth (YoY)+12.79%+45.83%
Net income (latest FY)$99.65M$-196.54M
Gross margin98.30%89.73%
Operating margin5.88%-101.19%
Net margin13.09%-103.57%
52-week high$126.38$122.20
52-week low$28.66$74.50
Distance from 52-week high-49.66%-8.05%
Analyst consensusbuystrong_buy
Avg. price target upside+124.14%+24.71%
Average volume1.26M1.10M
Shares outstanding109.44M69.33M
Employees730414
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RYTM has outperformed CORT by 28.1 percentage points over the past year.
  • Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
  • Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs +12.79%).

About Corcept Therapeutics

CORT stock →

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees

About Rhythm Pharmaceuticals

RYTM stock →

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees

CORT vs RYTM FAQ

Which is bigger, Corcept Therapeutics or Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $7.79B compared with $6.96B for Corcept Therapeutics (CORT).

Which stock has performed better over the past year, CORT or RYTM?

RYTM returned +10.44% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.

Are Corcept Therapeutics and Rhythm Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons